drugset / Trial / NCT07269496

Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

NCT07269496

Phase 1 Completed 16 enrolled SQ Innovation, Inc. BDD Pharma Ltd · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The trial is to compare the bioavailability of the original European Lasix (furosemide injection) administered in accordance with its prescribing information with the same dose of a novel furosemide formulation developed for this subcutaneous administration. The study will also investigate PK and PD of these regimens.

Timeline

Start
2026-02-09
Primary completion
2026-03-09
Completion
2026-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 80 mg Subcutaneous

Indications

No indication recorded.